Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology · Chronic Myelomonocytic Leukemia

How Do Doctors Tell Reactive Monocytosis From CMML?

At a Glance

A high monocyte count alone does not diagnose CMML. Doctors look for a count that stays high for at least three months and combine blood-count trends, cell examination, bone-marrow testing, and genetic studies; a count that falls after infection or inflammation is more likely reactive.

A high monocyte count (monocytosis) alone does not mean you have chronic myelomonocytic leukemia (CMML). Doctors tell the difference between CMML and a temporary “reactive” monocytosis by tracking your blood counts over time and performing specialized tests.

Because monocytes are white blood cells that fight infection and respond to tissue damage, their numbers naturally rise when your body is dealing with an illness. If the high count is caused by an infection or inflammation, it will usually return to normal once the underlying issue resolves [1][2]. If the count stays high, doctors will use microscopic reviews, bone marrow examinations, and genetic testing to evaluate if a blood disorder like CMML is present [3][4].

Safety Note: Seek urgent medical care if you experience emergency warning signs, such as uncontrolled bleeding, extreme shortness of breath, sudden confusion, or a high fever that could indicate a serious infection.

What Causes “Reactive” Monocytosis?

Reactive monocytosis happens when your bone marrow produces extra monocytes in a normal, healthy response to an external trigger. Once the trigger is gone, the count typically drops. Common examples include:

  • Infections: Bacterial infections (such as bacteremia, which is bacteria in the bloodstream) and severe viral infections (like COVID-19) can cause sharp, temporary spikes in your monocyte count [1][2].
  • Inflammatory and Autoimmune Diseases: Chronic inflammation forces the immune system to stay active, leading to persistently elevated monocytes [5]. Note that a reactive condition and CMML can sometimes exist at the same time [6].
  • Solid Tumors: Non-blood cancers can sometimes trigger an immune response that raises monocyte levels [7].
  • Recovery and Medications: Recovering from other blood disorders, rebounding from chemotherapy, or reacting to certain medications can temporarily elevate monocyte counts.

The Diagnostic Workup

To differentiate between a reactive immune response and a blood cancer, hematologists (blood specialists) use a step-by-step approach.

1. Repeat Complete Blood Counts (CBCs) and Clinical Review

Your lab report will show two monocyte numbers: the absolute monocyte count (the total number of monocytes per volume of blood) and the monocyte percentage (the portion of total white blood cells that are monocytes). Current diagnostic criteria for CMML generally require an absolute monocyte count of at least 0.5×1090.5 \times 10^9/L and a percentage of at least 10% that persists for more than 3 months [3].

For a stable patient with no other concerning symptoms, doctors often repeat the CBC over a 3-month period. A temporary fall in the count makes a reactive cause more likely, though it does not completely rule out a marrow disorder [2]. However, if you have other abnormal blood counts (like severe anemia or low platelets), an enlarged spleen, or significant symptoms (such as unexplained weight loss or night sweats), your doctor will not simply “give it time.” Instead, they will recommend a prompt hematology evaluation to investigate further [8][9].

2. Peripheral Blood Smear

Doctors will examine a sample of your blood under a microscope. In CMML, blood cells often look abnormal or poorly formed, a feature known as dysplasia [10][11]. They will also look for immature cells, called blasts and promonocytes, which should not normally be circulating in the blood [10].

3. Bone Marrow Biopsy

If your monocyte count remains high and reactive causes have been reasonably excluded, a bone marrow biopsy is required to evaluate for CMML [4]. This involves using local anesthetic to take a small sample of fluid and tissue from your hip bone (you may feel pressure during the sampling and soreness afterward). Pathologists examine this sample for dysplasia.

For a CMML diagnosis, the total combined number of blasts and promonocytes must be less than 20% in both the peripheral blood and bone marrow [3][12]. If the number is 20% or higher, doctors typically diagnose an acute leukemia instead [13].

Advanced Testing for CMML

No single test definitively diagnoses or rules out CMML on its own. Doctors integrate the results of several advanced tests:

  • Flow Cytometry: This test sorts and counts subtypes of monocytes. A pattern where “classical” monocytes make up 94% or more of the total monocytes strongly supports a CMML diagnosis [14][15]. However, severe inflammation can skew these results, so it is used as a supportive tool rather than a standalone diagnostic test [16][6].
  • Molecular Testing (Next-Generation Sequencing): Doctors test your blood or marrow for acquired genetic mutations to check for clonality (evidence of a genetically related population of blood cells). Over 95% of people with CMML have mutations in genes like TET2, SRSF2, or ASXL1 [3]. However, having one of these mutations does not automatically mean you have cancer, as they can occur naturally as people age (a condition called clonal hematopoiesis) [4]. Conversely, a negative test does not completely rule out CMML because some mutations might fall below the test’s detection limit.
  • Cytogenetic Testing: This looks for large changes in your chromosomes. It is crucial for ruling out other specific blood disorders that can mimic CMML, such as checking for the BCR::ABL1 fusion to rule out chronic myeloid leukemia (CML), or checking for other rearrangements like PDGFRA/B or FGFR1 [4][17].

Comparing Reactive Monocytosis and CMML

Feature Reactive Monocytosis Chronic Myelomonocytic Leukemia (CMML)
Duration Usually temporary; drops when the underlying trigger is resolved. Persistent; remains elevated for more than 3 months.
Common Triggers Infections, chronic inflammation, autoimmune conditions, or solid tumors. No external trigger; driven by acquired genetic changes in the bone marrow.
Associated Counts Other blood cells are usually normal or appropriately reacting to an illness. Often accompanied by low red blood cells (anemia) or low platelets.
Microscopic Findings Cells look mostly normal; no excess of immature cells. Cells appear abnormally shaped (dysplasia); may feature increased blasts and promonocytes (<20%).

Common questions in this guide

Does a high monocyte count automatically mean I have CMML?
No. Infections, inflammation, autoimmune disease, solid tumors, medications, and recovery from illness can cause reactive monocytosis. Doctors diagnose CMML by looking at the pattern over time and combining blood, marrow, microscopic, and genetic test results.
How long does a high monocyte count need to last before CMML is considered?
CMML criteria generally require an absolute monocyte count of at least 0.5 × 10^9/L and monocytes making up at least 10% of white blood cells for more than three months. Doctors may repeat CBCs during that period, but anemia, low platelets, an enlarged spleen, or significant symptoms can lead to earlier hematology evaluation.
What can a blood smear reveal when doctors are checking for CMML?
A blood smear lets doctors examine blood cells under a microscope. CMML may cause cells to look abnormal or poorly formed and may show immature cells called blasts or promonocytes; reactive monocytosis usually has cells that look more typical.
When is a bone marrow biopsy needed for monocytosis?
A bone marrow biopsy is usually considered when the monocyte count stays high and infection, inflammation, medication effects, and other reactive causes have been reasonably excluded. The sample helps pathologists assess abnormal cell development and measure blasts and promonocytes; a combined level of 20% or more generally points to acute leukemia rather than CMML.
Can flow cytometry or genetic testing confirm CMML by itself?
No. Flow cytometry can show a monocyte pattern that supports CMML, while molecular testing can find acquired mutations linked to the disease. Mutations can also occur with aging without cancer, and a negative test does not fully rule out CMML, so doctors interpret these results with the exam, blood counts, smear, and marrow findings.
What symptoms or blood-test findings should prompt faster evaluation?
Severe anemia, low platelets, an enlarged spleen, unexplained weight loss, night sweats, or other significant symptoms may lead to prompt hematology review rather than waiting for repeat counts. Uncontrolled bleeding, extreme shortness of breath, sudden confusion, or high fever requires urgent medical care.

Get notified when new evidence is published on chronic monocytic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Real world implementation of flow cytometric monocyte subset partitioning for distinguishing chronic myelomonocytic leukaemia from other causes of monocytosis.

    Barge L, Gooch M, Hendle M, Simleit E

    Pathology 2023; (55(6)):827-834 doi:10.1016/j.pathol.2023.05.006.

    PMID: 37541805
  2. 2

    Morphological Clues of Acute Monocytic Leukemia in COVID-19-Induced Transient Leukoerythroblastic Reaction with Monocytosis.

    Tam IS, Elemary M, DeCoteau J, et al.

    Hematology reports 2024; (16(2)):331-335 doi:10.3390/hematolrep16020033.

    PMID: 38921181
  3. 3

    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.

    Patnaik MM, Tefferi A

    American journal of hematology 2024; (99(6)):1142-1165 doi:10.1002/ajh.27271.

    PMID: 38450850
  4. 4

    Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.

    Shallis RM, Siddon AJ, Zeidan AM

    Current hematologic malignancy reports 2021; (16(3)):276-285 doi:10.1007/s11899-021-00632-6.

    PMID: 33890194
  5. 5

    Chronic myelomonocytic leukemia diagnosis and management.

    Chan O, Renneville A, Padron E

    Leukemia 2021; (35(6)):1552-1562 doi:10.1038/s41375-021-01207-3.

    PMID: 33714974
  6. 6

    [Analysis of peripheral blood monocyte subsets in chronic myelomonocytic leukemia: a single-center study].

    Wang L, Li MM, Bai JJ, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(10)):952-957 doi:10.3760/cma.j.cn121090-20250126-00045.

    PMID: 41339049
  7. 7

    Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia.

    Picot T, Aanei CM, Flandrin Gresta P, et al.

    Frontiers in oncology 2018; (8()):109 doi:10.3389/fonc.2018.00109.

    PMID: 29707521
  8. 8

    Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

    Itzykson R, Fenaux P, Bowen D, et al.

    HemaSphere 2018; (2(6)):e150 doi:10.1097/HS9.0000000000000150.

    PMID: 31723789
  9. 9

    [Diagnostic workup in front of an adult monocytosis].

    Labrousse J, Pasini S, Vignon G, et al.

    Annales de biologie clinique 2019; (77(5)):485-494 doi:10.1684/abc.2019.1475.

    PMID: 31486402
  10. 10

    Germline CSF3R Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms.

    Bochicchio MT, Micucci G, Asioli S, et al.

    International journal of molecular sciences 2023; (24(22)) doi:10.3390/ijms242216021.

    PMID: 38003211
  11. 11

    A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice.

    Schillinger F, Sourdeau E, Boubaya M, et al.

    Scandinavian journal of clinical and laboratory investigation 2018; (78(3)):159-164 doi:10.1080/00365513.2018.1423702.

    PMID: 29310473
  12. 12

    Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study.

    Foucar K, Hsi ED, Wang SA, et al.

    International journal of laboratory hematology 2020; (42(4)):418-422 doi:10.1111/ijlh.13212.

    PMID: 32297416
  13. 13

    How I diagnose and treat chronic myelomonocytic leukemia.

    Patnaik MM

    Haematologica 2022; (107(7)):1503-1517 doi:10.3324/haematol.2021.279500.

    PMID: 35236051
  14. 14

    ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.

    Wagner-Ballon O, Bettelheim P, Lauf J, et al.

    Cytometry. Part B, Clinical cytometry 2023; (104(1)):66-76 doi:10.1002/cyto.b.22054.

    PMID: 34967500
  15. 15

    Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.

    Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al.

    Blood 2015; (125(23)):3618-26 doi:10.1182/blood-2015-01-620781.

    PMID: 25852055
  16. 16

    Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?

    Solary E, Wagner-Ballon O, Selimoglu-Buet D

    Best practice & research. Clinical haematology 2020; (33(2)):101134 doi:10.1016/j.beha.2019.101134.

    PMID: 32460985
  17. 17

    Case report: Co-existing chronic myeloid leukemia and chronic myelomonocytic leukemia-A clinically important but challenging scenario.

    Song J, Moscinski L, Zhang L, Zhang H

    Leukemia research reports 2023; (20()):100378 doi:10.1016/j.lrr.2023.100378.

    PMID: 37415731

This page is for informational purposes only and does not constitute medical advice. A hematologist should interpret your blood counts and decide whether further testing is needed.